Ascentage Pharma announced that it has released updated clinical results of olverembatinib, a third-generation tyrosine kinase inhibitor, in patients with TKI-resistant succinate dehydrogenase -deficient gastrointestinal stromal tumor, in a Poster Presentation at the 59th American Society of Clinical Oncology Annual Meeting.
